Skip to content

Music for Sleep-onset Insomnia

God Nat - God Dag. A Randomized Controlled Trial of Bedtime Music as Early Intervention for Sleep-onset Insomnia

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04585425
Enrollment
60
Registered
2020-10-14
Start date
2021-05-01
Completion date
2023-06-02
Last updated
2023-12-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insomnia

Brief summary

The study is a randomized controlled trial evaluating the effect of bedtime music as an early intervention for sleep-onset insomnia in adults. The investigators use a randomized controlled trial design with two parallel groups. All participants receive sleep hygiene advice as standard treatment and participants in the intervention group are additionally asked to listen to a sleep playlist daily at bedtime. Subjective and objective sleep measures are evaluated before and after the 4 weeks intervention period. In addition, follow-up measures of subjective outcomes are assessed 4 weeks after the end of the intervention period.

Interventions

Participants receive standard sleep hygiene advice.

BEHAVIORALBedtime music listening

Participants in the intervention group listen to their preferred sleep playlist daily at bedtime for minimum 30 minutes.

Sponsors

University Hospital Heidelberg
CollaboratorOTHER
University College Nordjylland
CollaboratorUNKNOWN
University of Oxford
CollaboratorOTHER
Sygekassernes Helsefond
CollaboratorOTHER
University of Aarhus
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Sleep-onset insomnia for 3-18 months

Exclusion criteria

1. use of medications (benzodiazepines, z-drugs, antidepressive and anti-psychotic drugs) 2. alcohol or substance abuse 3. pregnant or breastfeeding women 4. other sleep disorders (e.g. sleep apnea, restless leg syndrome, etc.) 5. current psychiatric disorder or a history of psychotic disorders 6. somatic disorders interfering with sleep (e.g. critical illness, pain disorders, neuro-degenerative disorders) 7. shift work.

Design outcomes

Primary

MeasureTime frameDescription
Insomnia severityChange from baseline to after the 4-week intervention period.Measured with the Insomnia Severity Index, range 0-28 with higher scores indicating more severe insomnia.

Secondary

MeasureTime frameDescription
Sleep qualityChange from baseline to after the 4-week intervention period.Measured with the Pittsburgh Sleep Quality Index, range 0-21 with higher scores indicating more sleep problems.
Sleep initiation difficultiesChange from baseline to after the 4-week intervention period.Difficulties initiating sleep as measured with Pittsburgh Sleep Quality Index subscale
Objective sleep qualityChange from baseline to after the 4-week intervention period.Objective sleep quality as measured with polysomnography
Quality of lifeChange from baseline to after the 4-week intervention period.Quality of life as measured with SF-36, range 0-100 with higher scores indicating better quality of life.
Pre-sleep arousalChange from baseline to after the 4-week intervention period.Pre-sleep arousal as measured with the Pre-Sleep Arousal Scale, range 8-40 with higher scores indicating higher pre-sleep arousal.
Sleep-wake patternChange from baseline to after the 4-week intervention period.Sleep-wake pattern as measured with wrist-actigraphy

Other

MeasureTime frameDescription
Depressive symptomsChange from baseline to after the 4-week intervention period.Depressive symptoms as measured with Beck Depression Inventory II, range 0-63 with higher scores indicating more severe depression.
AnxietyChange from baseline to after the 4-week intervention period.Anxiety as measured with the State-Trait Anxiety Inventory, range 0-80 with higher scores indicating more anxiety.

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026